We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Avacta Group Plc | AVCT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 1.00 | 1.41% | 72.00 | 10:26:24 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 70.50 | 70.25 | 73.50 | 72.00 | 71.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 09/7/2024 09:16 by cheshire pete Clarity is indeed the difference. No more 'shortly' or vague seasonal targets. Clarity gives investors confidence. Traders feed off vagueness and optimistic statements.Think the 'concerns' over the next CLN conversion are overblown. Sense traders banging on trying to create volatility for their next 50 quid. Bigger picture. |
Posted at 06/7/2024 12:18 by vasilis Very true as regards the value of the creation of a Scientific Advisory Board (SAB) as clearly shown here - The SAB in itself brings not only a new level of 'gravitas' to the company, but it also signals to Institutional Investors in particular that a more rigorous and strategic approach is now the new standard at Avacta which in my opinion was very much lacking under the previous CEO. Extremely pleased with Christina - our new CEO - and with her strategy so far. Long may it continue as this is just the beginning in my view. |
Posted at 29/5/2024 16:10 by bones698 White utter nonsense as usual over 90% of small caps stocks will lose investors money that's why it's a complete gamble and with bad odds. Everyone thinks they have got one of the 10% that comes good but the relaity is they haven't and will lose money.More importantly is when you buy and sell any of them and getting that timing right is crucial to being able to make money in small cap companies. Loom at any number that have raised money recently at huge discounts on already depressed share prices. Most investors are down over 90% on them as you well know. That said if your buying them now you stand a good chance to make money provided they can show some good news in the coming months. The ones that tend to lose are those investing for the long term at the wrong time in the cycle, paying to high a price for hopes and dreams that are years away and need cash to get there. Avacta is such a case imo and we have already seen the share price fall massively because of this Imo there is more of the same to come and with its 120m mkt cap it looks almost certain to fall further as more cash will be required and they are so far away from any revenues or break even from the drugs in trials. I don't hold a lot of shares I post on but I am entitled to my opinion and it's usually in stark contrast to many ramping those shares. The fact I don't hold doesn't stop me having an opinion and commenting on them as those that hold them usually are biased and fail to see the downside. Again just look back here and at mnay other companies. With that in mind and the success rate being so low it's usually the negative posters which are correct and should be listened to a lot more, sadly though how many actually do or end up losing money because they don't shows how silly some investors are when the facts back this up |
Posted at 24/5/2024 21:52 by jaknife john henry,Don't be a donkey. Let me post the words again so you can read what I've actually written not the words that you've dreamt of: ==================== The "scam" (if you like) with Avacta is that they've suckered investors into somehow thinking that the amazing wonderful PRECISION platform somehow created/designed AVA 6000. That's not the case! There is a medical university out in the US called "Tufts", it's where pretty much all old failed drugs/molecules/ther If you want to start a lifestyle company in the UK and raise a load of cash from investors then you go to Tufts, license some of their drugs and then start to publish wild rampy RNSs. Take a look at Tiziana Life Sciences (TILS) for an example of where that was last done in a really blatant manner. Avacta is similar. They went to Tufts sometime in 2019 and acquired AVA 6000 from Tufts. At that time the treatment was known as "ARI-6000", it had been acquired from the bankrupt estate of the company Arisaph Pharmaceuticals. Arisaph had put ARI-6000 through both Phase 1 and Phase II trials but had failed to achieve commercial success. The company went into liquidation and *NO MAJOR PHARMA COMPANY* was interested in acquiring the technology. Hence the treatment went to Tufts, which is where pretty much all dog-end drugs end up in the US. Avacta have essentially replicated the same work that Arisaph did on ARI-6000 whilst telling wonderful stories to shareholders. Meanwhile Big Pharma has focused its work on complete different cancer therapies including targeted cancer therapies that have a completely different cleaving mechanism (and are already FDA approved), gene therapies and modified viruses. Big Pharma has zero interest in AVA 6000, they could have bought it themselves from Tufts but Avacta still dangled the idea that they might get big license payments whilst instead diluting shareholders on a regular basis including with a toxic death spiral convertible. Meanwhile Smith took outrageous remuneration - rewards for failure. With a new CEO, Avacta might be able to keep the plates spinning for a few more years and might even be able to raise yet more money from shareholders but there's no reason why they won't fail with AVA 6000 in exactly the same way that Arisaph failed when they called it "ARI-6000"! JakNife ==================== |
Posted at 22/4/2024 16:54 by jaknife PWhite73,"Jaknife - "You need to use the 10% discount to VWAP part of the formula" Come on spit it out. What is the VWAP price they are using over how many days and which days?" I posted the formula in 57,557: ==================== Share Payments: For any interest and amortisation payments made in Ordinary Shares (which shall be subject to certain conditions including no potential event of default having occurred and maintenance of a minimum free float), the Ordinary Shares to be delivered shall be calculated by dividing the interest or amortisation amount due by the lower of (a) the prevailing conversion price, in each case on the applicable repayment date and (b) 90 per cent. of the Market Price per Ordinary Share (as defined below) The "Market Price" is the lower of the arithmetic average of the VWAP for the Ordinary Shares: (i) on the ten (10) trading days, ending on the applicable date or (ii) on the five (5) trading days, ending on the applicable date, but in no event shall it be greater than the VWAP of the Ordinary Shares on the applicable date ==================== "RNS 18/10/2022 - "Convertible Bond Investor agrees not to sell Ordinary Shares (or any interest in them) nor engage in any short sale transactions in Ordinary Shares (or any interest in them) of the Company during any relevant calculation period, subject to certain exceptions" As I noted above, the Investor is a subsidiary of a large market maker (Susquehanna). The restrictions that you've posted above apply to "Investor", however, they don't apply to the market maker, which is a separate legal entity. "No it is not and it's important to understand the difference between the two. Nobody was screaming death spiral finance when this hit 180p in February last year." We don't agree on this point but you will find that I was noting that this was a death spiral convertible right from day one, when it was first issued and presented in a manner that made people think that it was a genuine convertible rather than a death spiral convertible. It's amusing but the investor into this death spiral is the same as the investor into the Pantheon Resources death spiral. The PANR shareholders also insisted for many months that it wasn't a death spiral, however, now they accept that it is! JakNife |
Posted at 22/4/2024 15:05 by pwhite73 Jaknife - "You need to use the 10% discount to VWAP part of the formula"Come on spit it out. What is the VWAP price they are using over how many days and which days? Jaknife - "Better than that, the investor into the loan note is a subsidiary of a large market maker (Susquehanna) and market makers are legally permitted to naked short (and are also exempt from the short selling disclosure rules). Hence, between them, the investor and Susquehanna can forward sell the shares!" RNS 18/10/2022 - "Convertible Bond Investor agrees not to sell Ordinary Shares (or any interest in them) nor engage in any short sale transactions in Ordinary Shares (or any interest in them) of the Company during any relevant calculation period, subject to certain exceptions" |
Posted at 11/4/2024 15:26 by jaknife jacktrax,"Taking part in that placing Jak , the one for existing shareholders , so you held shares Jak , give me the clever words and shoot me down but I think you are telling porkies" The placing was open to any professional investor. You didn't need to be a shareholder to participate. If you read the original placing RBS, for example, you will find the words: "The Placing will be conducted through an accelerated bookbuild (the "Bookbuild") which will be launched immediately following this announcement (being, together with the Appendices hereto, this "Announcement") and will be made available to new and existing institutional investors." [my bold] see: JakNife |
Posted at 26/3/2024 18:47 by ohwhatfun Avacta stuck out like a sore thumb, flying high in a market where promising ideas have been destroyed. Many diluted into oblivion or now bust.The Avacta crazy market cap was down to a long run of excessive pumping by Myles and co, to a retail army oblivious to/stubborn ignorance of the risks. A fund raise was nailed on and at significant discount, a plethora of small caps have followed the same fate. It was blatantly obvious what was coming but due the fantasy forecasts in notes by the pumpers along with a social media frenzy, ably assisted by the CEO, private investors got mugged. The blame lies entirely with the fantasy crew, completely ignoring the obvious, including positive posts, dragging in buyers, just before the guillotine fell. Investors thought the pumpers had inside information, raise not coming, ignore the warnings. This remains very high risk, and will do for quite some time. The pumping frenzy simply offered an opportunity for some to go short, who anticipated, with good reason, that a heavily discounted raise would come. It did, they were right, believed favoured pump crew, wrong. That’s about it, stop trying to deflect the reality, the CEO and pump crew sucked in buyers, and stiffed them good and proper. |
Posted at 21/2/2024 10:13 by ohwhatfun LogSome points. Avacta is far too early in process (trials) to attract backers, the numbers involved are too low. Hence that is a very slim chance event. Even then it appears increased doses failed to meet the same standard as the original Dox, safety up efficacy not. Not an efficacy trial they say, safety, but it's sample of efficacy regardless of the phase 1 label. There are a host of phase 1 safety trials where efficacy has been better than the standard of care. April, Bond. I'm trying to get my head around the bond, your April comment, floor reset 18 months, the lower limit appears to be 95p But then it states "save in limited circumstances there is a reset price floor of 95p" No explanation of that, but I guess the limited circumstances relate to share price performance (EG 95p breached), so that floor of 95p is likely to drop, potentially materially. The bond can also convert partially at any time at the bond holders discretion. As is typical, the full details about the bond are not in there. Always fun to see negativity thrown at warning posts about how vicious the city can be when it comes to fund raise time. Pure tunnel vision by the city vultures, crash it as much as possible to maximise returns, they don't give a damn about the company. Private investors seem to fight against what is blatantly obvious, a hope that some Good Samaritan will appear with the cash, ignoring the likely discounted fund raise reality. Fingers crossed there are not too many private investors geared beyond their means, there are always some, and no doubt sleepless nights already in play. I do not wish those crash events on them, it's vile, they get wiped out, the city does not care, it's just another successful day at the office to them, |
Posted at 19/2/2024 09:28 by loglorry1 I have no clue if their story holds up and unless you have a PhD and a lot of experience in the exact field nor do you. I very much doubt anyone on this board has the expertise to evaluate their claims and probably none of the private investors that hold the shares does either. Even if they did they wouldn't have access to the data required to evaluate their claims.There are no peer reviewed independently funded papers of their claims either which is a red flag for me. The company engages in a massive amount of financial PR targeted at private investors another red flag. Saying all that if enough people believe and buy the shares the share price will go up. From what I know of your posts on CINE PWhite, your analysis of these situations isn't much good either. Do you have the experience and relevant data to provide input on the science? From what I can tell of @tickboo is that he buys story stocks. I don't think he has any track record of success but like everyone he might have got a bit lucky here and there. He probably sold a lot of his holding much higher but he'll never admit it. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
